A Novel Vector system that I Specifically Eliminate Tumorigenic Cells in Pluripotent Stem Cells.
| Project/Area Number |
15K19389
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
IDE Kanako 鹿児島大学, 医歯学総合研究科, 特任研究員 (20725791)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | ES/iPS細胞 / 腫瘍化阻止 / 心筋細胞 / 再生医療 / ヒトES/iPS細胞 / レンチウイルスベクター |
|---|
| Outline of Final Research Achievements |
Human pluripotent stem cells (hPSCs) are a promising source of regenerative material for clinical applications. However, hPSC transplant therapies pose the risk of teratoma formation and malignant transformation of undifferentiated remnants. Researchers have recently embarked on studies aimed at locating and directly treating hPSC-derived tumorigenic cells. In particular, novel approaches to directly killing tumorigenic cells are expected to improve the safety of hPSC-based therapy.
Here, we developed a novel method for efficiently generating diverse tumorigenic cell-targeting lentiviral vectors(TC-LVs), which can specifically and efficiently kill tumorigenic cells in transduced hPSCs. This study demonstrates the utility of this methodology and reveals that the products, including hPSCs with the suicide gene downstream of the tumor specific promoter, should pave the way toward safe clinical applications of hPSC-based regenerative medicine.
|
Report
(4 results)
Research Products
(12 results)
